摘要
目的探讨PIK3CA在妇科肿瘤中的基因突变情况,并分析其与患者生存时间的关系。方法选取2017年1月至2021年1月广东药科大学附属第一医院妇科收治的110例妇科肿瘤患者的肿瘤组织样本,其中子宫内膜癌30例、宫颈癌40例、卵巢癌40例。检测110例妇科肿瘤患者PIK3CA基因突变,分析其与患者预后的关系。结果110例患者中PIK3CA基因突变61例(55.45%),最常见的碱基突变为:c.G1633A。宫颈癌和卵巢癌中PIk3CA突变率较高,分别为57.5%和67.5%。宫颈癌和卵巢癌患者癌组织与癌旁组织PIK3CA基因突变发生率比较,差异有统计学意义(P<0.05)。宫颈癌和卵巢癌PIK3CA突变型患者生存时间短于PIK3CA野生型,差异有高度统计学意义(P<0.01);子宫内膜癌PIK3CA突变型与野生型比较,差异无统计学意义(P>0.05)。结论在妇科肿瘤中存在PIk3CA基因突变,其中在卵巢癌和宫颈癌中尤为多见,并与患者生存时间有密切关系。
Objective To investigate PIK3CA gene mutation in gynecological tumors and to analyze its relationship with the survival time of patients.Methods The tumor tissue samples of 110 patients with gynecological tumors admitted to the First Affiliated Hospital of Guangdong Pharmaceutical University from January 2017 to January 2021 were selected,including 30 cases of endometrial cancer,40 cases of cervical cancer,and 40 cases of ovarian cancer.PIK3CA gene mutation was detected in 110 patients with gynecological tumors,and the relationship between PIK3CA gene mutation and prognosis was analyzed.Results Among 110 patients,61 cases(55.45%)had PIK3CA gene mutation,and the most common base mutation was c.G1633A.The mutation rates of PIK3CA in cervical cancer and ovarian cancer were 57.5%and 67.5%,respectively.There was statistical significance in the incidence of PIK3CA gene mutation between cancer tissues and adjacent tissues in patients with cervical cancer and ovarian cancer(P<0.05).The survival time of patients with PIK3CA mutation type in cervical cancer and ovarian cancer was shorter than that of PIK3CA wild type,and the difference was highly statistically significant(P<0.01);there was no significant difference between PIK3CA mutant type and wild type in endometrial cancer(P>0.05).Conclusion PIk3CA gene mutation exists in gynecological tumors,especially in ovarian cancer and cervical cancer,and is closely related to the survival time of patients.
作者
郭苑莉
陶莹
廖凤儿
吴敏敏
肖培洪
杜静
杨文生
GUO Yuanli;TAO Ying;LIAO Fenger;WU Minmin;XIAO Peihong;DU Jing;YANG Wensheng(Department of Obstetrics and Gynecology,the First Affiliated Hospital of Guangdong Pharmaceutical University,Guangdong Province,Guangzhou510080,China)
出处
《中国医药导报》
CAS
2023年第14期25-28,共4页
China Medical Herald
基金
广东省医学科学技术研究基金项目(A2022318)。
